Close Menu
Affymetrix last week reported that total third-quarter revenues declined 21 percent amid weak sales to pharma and academic customers, while restructuring charges helped swing last year’s profit to a loss in the current period.
 
A senior company official said the numbers “disappoint us” and do not reflect Affy’s “long-term potential,” and said the firm has created a three-point plan to revitalize sales.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.

Mar
17
Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.